$2.99+0.07 (+2.40%)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
Purple Biotech Ltd in the Healthcare sector is trading at $2.99 with a market capitalization of $3M. Wall Street consensus targets $30.00 (1 analysts), implying a +903.3% move over the next 12 months. The stock is currently near its 52-week low of $2.52, remaining 52.2% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that bl...